Oslo, Norway, 30 March 2023
The Board of Directors of Nordic Nanovector ASA has decided to postpone the
upcoming Annual General Meeting (AGM), which was originally scheduled for 26
April.According to Oslo Børs regulations, the Company must hold its AGM before
[date]. A new date for the AGM will be announced as soon as possible.
Meanwhile, the Company continues to work with potential strategic transactions
or partnership that will deliver value for all stakeholders, and will come back
with more information in due course.
For further information, please contact:
IR enquiries
Ludvik Sandnes, Interim CEO & CFO
Cell: +47907 43 017
Email:ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email:nordicnanovector@medistrava.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. Further
information can be found
atwww.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=
h
ttp%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava
.
com%7Cbd8fdb7f05284d3963a108d9d20ae447%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C
0
%7C637771766496096573%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMz
I
iLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=xp8WBxqCMdEa4qM%2FjJAyw9bnfalGpQqsw
X
zSzRJqqWo%3D&reserved=0).